ORAP
As listed in the register: ORAP
4 mg · tablet
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Pimozide
- Made by
- Aa Pharma Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Pimozide). It describes the substance, not this exact product.
Pharmacodynamic Actions Pimozide tablets, are an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system.
Although its exact mode of action has not been established, the ability of pimozide to suppress motor and phonic tics in Tourette’s Disorder is thought to be a function of its dopaminergic blocking activity.
Pimozide is extensively metabolized, primarily by N-dealkylation in the liver.
Effects of food and disease upon the absorption, distribution, metabolism and elimination of pimozide are not known.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-12
Safety of the active substance
From the US prescribing label for the same active substance (Pimozide). It describes the substance, not this exact product.
- Pimozide is contraindicated in the treatment of simple tics or tics other than those associated with Tourette’s Disorder. 2.
- Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. 3.
- Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). 4.
- Pimozide is contraindicated in patients with severe toxic central nervous system depression or comatose states from any cause. 5.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
FranceNo exact match for this strength and form
Netherlands3 matching products
Details
| Made by | Aa Pharma Inc |
|---|---|
| Active substance | Pimozide |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 4 mg |
| Form | tablet |
| Classification | N05AG02 · Pain, sleep, mood, epilepsy and the brain |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Dormant |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 00313823 |
| DPD drug code | 2059 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 2 mg
- 4 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.